Affiliation:
1. Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London , London EC1M 6BQ , United Kingdom
2. Faculty of Life Sciences and Medicine, King’s College London, Guy’s Campus , London SE1 1UL , United Kingdom
3. Department of Paediatric Endocrinology, Great Ormond Street Hospital NHS Trust , London WC1N 3JH , United Kingdom
4. Department of Paediatric Endocrinology, Royal London Children’s Hospital, Barts Health NHS Trust , London E1 1BB , United Kingdom
Abstract
Abstract
Objective
Hypogonadotropic hypogonadism is characterized by inadequate secretion of pituitary gonadotropins, leading to absent, partial, or arrested puberty. In males, classical treatment with testosterone promotes virilization but not testicular growth or spermatogenesis. To quantify treatment practices and efficacy, we systematically reviewed all studies investigating gonadotropins for the achievement of pubertal outcomes in males with hypogonadotropic hypogonadism.
Design
Systematic review and meta-analysis.
Methods
A systematic review of Medline, Embase, Global Health, and PsycINFO databases in December 2022. Risk of Bias 2.0/Risk Of Bias In Non-randomized Studies of Interventions/National Heart, Lung, and Blood Institute tools for quality appraisal. Protocol registered on PROSPERO (CRD42022381713).
Results
After screening 3925 abstracts, 103 studies were identified including 5328 patients from 21 countries. The average age of participants was <25 years in 45.6% (n = 47) of studies. Studies utilized human chorionic gonadotropin (hCG) (n = 93, 90.3% of studies), human menopausal gonadotropin (n = 42, 40.8%), follicle-stimulating hormone (FSH) (n = 37, 35.9%), and gonadotropin-releasing hormone (28.2% n = 29). The median reported duration of treatment/follow-up was 18 months (interquartile range 10.5-24 months). Gonadotropins induced significant increases in testicular volume, penile size, and testosterone in over 98% of analyses. Spermatogenesis rates were higher with hCG + FSH (86%, 95% confidence interval [CI] 82%-91%) as compared with hCG alone (40%, 95% CI 25%-56%). However, study heterogeneity and treatment variability were high.
Conclusions
This systematic review provides convincing evidence of the efficacy of gonadotropins for pubertal induction. However, there remains substantial heterogeneity in treatment choice, dose, duration, and outcomes assessed. Formal guidelines and randomized studies are needed.
Funder
NIHR Academic Clinical Fellowship
NIHR
NHS
UK Department of Health and Social Care
Wellcome Trust
Barts Charity
Publisher
Oxford University Press (OUP)
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism
Reference90 articles.
1. Congenital hypogonadotropic hypogonadism, functional hypogonadotropism or constitutional delay of growth and puberty? An analysis of a large patient series from a single tertiary center;Varimo;Hum Reprod.,2017
2. Congenital hypogonadotrophic hypogonadism: minipuberty and the case for neonatal diagnosis;Swee;Front Endocrinol (Lausanne).,2019
3. Kallmann syndrome;Dodé;Eur J Hum Genet.,2009
4. Male acquired hypogonadotropic hypogonadism: diagnosis and treatment;Salenave;Ann Endocrinol (Paris).,2012
5. Minipuberty: why does it happen?;Becker;Horm Res Paediatr.,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献